Clinician-guided low-dose protocol addresses proven gap in preventive care—intervening before disease progresses

Found, the doctor-designed telehealth platform specializing in personalized weight care since 2019, today announced the launch of its GLP-1 Microdosing Program. The program addresses a critical gap in preventive care: patients with early metabolic dysfunction often wait years for treatment until their condition worsens to meet traditional prescribing thresholds.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251028348303/en/

Found Health launches a GLP-1 Microdosing Program, targeting early metabolic dysfunction before disease progresses.

"For too long, healthcare has ignored the sophisticated signals our bodies send about metabolic health—and worse, dismissed the women who were paying attention to those signals," said Luca Ranaldi, CEO of Found. "Our microdosing program represents healthcare that finally listens—validating what you already know about your body, intervening when symptoms impact daily life and when prevention can have the most profound impact."

The Preventive Care Gap

With 1 in 3 American adults living with metabolic syndrome and 98 million Americans having prediabetes, millions experience documented metabolic dysfunction yet face barriers to treatment. Traditional healthcare protocols often require patients to progress further into disease—reaching specific BMI cutoffs or developing type 2 diabetes—before prescribing GLP-1 medications, despite mounting evidence that earlier intervention may prevent progression.

This gap particularly affects women with PCOS and those navigating perimenopause and menopause. Women with PCOS—a condition affecting 1 in 10 women and linked to insulin resistance in up to 70% of cases—face barriers to medications that could address the root metabolic dysfunction, not just symptoms. Similarly, when estrogen and progesterone levels decline during perimenopause and menopause, metabolic balance fundamentally shifts: insulin resistance increases, appetite regulation changes, inflammation rises, and the risk of developing type 2 diabetes climbs significantly. Yet women experiencing these measurable changes are often told it's simply normal aging and offered only lifestyle modifications.

Across both populations, patients find themselves in healthcare limbo—told their numbers aren't concerning enough for intervention despite documented metabolic dysfunction that will likely progress without treatment.

Found's GLP-1 Microdosing Program provides personalized, clinician-supervised treatment for patients with documented metabolic conditions such as prediabetes, PCOS with insulin resistance, metabolic syndrome, or family history of type 2 diabetes combined with metabolic risk factors.

Evidence-Based Early Intervention

Emerging research shows GLP-1 medications offer benefits beyond weight loss for patients experiencing metabolic dysfunction. Clinical evidence demonstrates these medications may:

• Reduce risk of progressing from prediabetes to type 2 diabetes by up to 94%
• Improve insulin resistance markers in PCOS patients
• Help normalize appetite regulation and reduce inflammatory markers
• Support cardiovascular health, even at lower doses
• Address the metabolic shifts that occur during hormonal transitions

For women in perimenopause and menopause—when hormonal changes directly impact insulin sensitivity and diabetes risk—early intervention with GLP-1s may help stabilize the metabolic disruption driving these changes. If biomarkers already indicate metabolic dysfunction during this transition, the evidence increasingly supports acting now rather than waiting for progression to diabetes.

"When we see documented prediabetes, insulin resistance from PCOS, or metabolic changes during menopause, we have clear evidence that intervention can prevent progression to diabetes," said Rekha Kumar, MD, MS, Senior Medical Advisor for Found. "Yet we routinely deny treatment to patients with documented metabolic dysfunction simply because they haven't crossed arbitrary thresholds. Found's approach to microdosing GLP-1s matches treatment intensity to metabolic stage, raising the standard for personalized, preventive care."

Personalized Treatment Plans, Not Generic Protocols

At Found, microdosing serves two distinct clinical purposes, each carefully matched to where patients are in their metabolic journey.

For people with early metabolic risks and lower BMIs, microdosing can be preventive care—intervening when lower doses may be most effective at addressing emerging dysfunction before it progresses. This isn't maintenance or a generic entry point; it's targeted intervention for a specific population whose metabolic signals call for early action.

For some patients with higher BMIs or more complex metabolic needs, microdosing can serve as an initial approach to minimize side effects while the body adjusts to GLP-1 therapy. This is distinct from our preventive microdosing program—it's part of Found's broader "start low, go slow" titration approach that has made our care model successful across all dose levels, with the goal of building toward therapeutic doses as tolerated.

This distinction matters: while some competitors have repurposed "microdosing" as a one-size-fits-all protocol regardless of metabolic profile, Found's approach is clinically defined and patient-specific. We match the dose—and the clinical rationale—to each individual's metabolic stage, risk factors, and treatment goals.

More than 80% of Found members across all dose levels report no side effects, demonstrating that personalized, ongoing care—not dose size alone—drives tolerability and sustainable outcomes.

Comprehensive Clinical Support

Found's program combines medication with whole-person support. Members have access to:

• One of the industry's most extensive medication formularies with 15+ medication options tailored to individual needs and preferences.

• Expert clinical oversight from clinicians trained in Found's unique approach, who design personalized treatment plans and provide ongoing care optimization.

• Dedicated care team support for seamless medication management, side effect monitoring, and dose adjustments based on individual response.

• One-on-one lifestyle and behavioral coaching to help members build sustainable habits and navigate their unique health journey.

• Integrated digital and community support with progress tracking tools, educational resources, community connection, and Aimee—Found's AI health companion—to help members stay motivated and engaged between clinician visits.

Availability

Found's GLP-1 Microdosing program launches immediately in select states nationwide, with continued expansion throughout 2025. Eligible patients begin with a comprehensive telehealth evaluation through Found's platform, where board-certified clinicians assess labs, health history, and individual risk factors before designing personalized treatment protocols.

About Found

Found is a physician-designed weight care platform transforming the way society approaches personalized weight management. Founded in 2019, Found provides members with one of the industry's largest medication formularies alongside judgment-free, evidence-based care that combines medication and behavior change support. This comprehensive approach drives lasting results while reducing costs for consumers, employers, and payors. Named one of the best weight loss programs in the United States by Forbes and USA Today, Found is also a member of the Strategies to Overcome and Prevent (STOP) Obesity Alliance. For more information, visit joinfound.com/microdosing.

Compounded GLP-1s are not reviewed by the FDA for safety, efficacy, or quality, and are not approved to treat any specific condition. Individual results may vary. Prescriptions are provided only if clinically appropriate after evaluation by a licensed provider.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251028348303/en/